Updated from 8:35 a.m.
Shares in the U.K-based drugmaker AstraZeneca (AZN - Get Report) fell Monday after an advisory committee of the Food and Drug Administration late Friday dealt a staggering blow to the company's experimental blood thinner Exanta, saying the risks of liver damage outweighed the benefits.
The panel rejected AstraZeneca's entire application that Exanta be approved for three uses related to preventing blood clots, Reuters reported Friday.
The FDA is expected to act on the panel's recommendations by late October. The agency doesn't have to follow its advisers' suggestions, but it usually does so.Shares were off $1.60, or 3.7%, to $42.14. AstraZeneca had asked the FDA to approve the drug for preventing blood clots in veins for patients undergoing knee-replacement surgery; preventing stroke and other clot-induced complications of the erratic heartbeat known as atrial fibrillation; and long-term prevention of blood clots in veins after a patient has gotten a standard blood clot treatment. But once the advisory panel rejected the knee-replacement-surgery application, it was clear that Exanta was in trouble. Analysts had viewed knee surgery as Exanta's best chance because the European Union has approved the drug for preventing blood clots after elective knee and hip surgeries. In the company's U.S. application, knee surgery would have only required, at most, 12 days of treatment with the drug, whereas the other indications would have required long-term use of Exanta. In addition, the FDA panel rejected as inadequate the company's proposed monitoring plan to protect Exanta users against liver damage. The advisory committee voted after markets had closed. AstraZeneca's stock closed Friday at $43.74, losing 66 cents, or 1.5%, on trading volume that was 6 times the daily average. But in after-hours trading, the stock was down another $1.29, or 3.3%. On Thursday, an unfavorable FDA staff report used as guidance for the advisory committee sent the stock down 5.6% on trading volume that was 11 times greater than average. The report